Global Crizotinib Market growing at a CAGR of 5.6% from 2023 to 2031
Category : Healthcare | Published Date : Dec 2023 | Type : Press Release
Key Market Overview
Consegic Business Intelligence analyzes that the crizotinib market is predicted to grow at a compound annual growth rate of 5.6% from 2023 to 2031 and is expected to reach USD 1,505.14 million in 2031 which was valued at USD 923.08 million in 2022 and 970.48 million in 2023.
The report highlights the significant increase in the adoption of crizotinib in the pharmaceutical industry, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the crizotinib market.
Global Crizotinib Market By Overview
The crizotinib market is bifurcated into capsule and application. Based on capsule, the market is segmented into 250mg capsule and 200mg capsule. In 2022, the 250mg capsule segment dominated in the overall crizotinib market. Based on application, the market is categorized into ALK-positive NSCLC and ROS1-positive NSCLC. In 2022, the ALK-positive NSCLC segment accounted for the highest market share in the crizotinib market.
Get Free SampleMarket Dynamics
Driver:
- Rising prevalence of non-small cell lung cancers across the world contributing to the growth of the market.
- Increasing effectiveness of targeted therapy and precision medicines in the treatment of lung cancers.
Restraints:
- Side effects associated with the consumption of crizotinib drug is restraining the market growth.
Market Segmentation:
| Report Attributes | Report Details |
| By Capsule | 200mg capsule and 250mg capsule |
| By Application | ALK-positive NSCLC and ROS1-positive NSCLC |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Pfizer, Incepta Pharmaceuticals Ltd, and MANUS AKTTEVA BIOPHARMA LLP., among others which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the crizotinib market is expected to witness substantial growth in the coming years due to the rise in the adoption of crizotinib for lung cancer treatment.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Pfizer
- Bulat Pharmaceutical
- Beacon Pharmaceuticals PLC
- Selleck Chemicals
- Incepta Pharmaceuticals Ltd
- Shanghai Hope-Chem Co.,Ltd
- WUHAN HANWAYS PHARMCHEM CO., LTD.
- DEAFARMA
- Apothecon Pharmaceuticals Pvt Ltd.
- LGM Pharma
- Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
- MANUS AKTTEVA BIOPHARMA LLP
- Vea Impex (I) Pvt. Ltd
